On June 17, 2024, the board of directors, or the Board, of Fulcrum Therapeutics, Inc., or Fulcrum, increased the size of the Board from eight to nine members, and upon recommendation from the Nominating and Corporate Governance Committee of the Board, elected Colin Hill as a member of the Board, effective June 17, 2024, to serve as a Class I director with a term expiring at Fulcrum?s 2026 annual meeting of stockholders and thereafter until his successor has been duly elected and qualified or until his earlier death, resignation or removal. Mr. Hill was appointed to serve on the Science & Technology Committee. The Board has determined that Mr. Hill is ?independent?

as contemplated by the Nasdaq Stock Market and other governing laws and applicable regulations.